Drug Type Inactivated vaccine, Prophylactic vaccine, Multivalent vaccine + [1] |
Synonyms Multivalent Pneumococcal conjugate vaccine, Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal conjugate vaccine + [13] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (08 Jun 2021), |
RegulationFast Track (United States), Priority Review (United States), Breakthrough Therapy (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
invasive Streptococcus pneumoniae infection | South Korea | 31 Oct 2024 | |
Otitis Media | United States | 27 Apr 2023 | |
Pneumococcal Infections | Canada | 09 May 2022 | |
Pneumonia, Pneumococcal | European Union | 14 Feb 2022 | |
Pneumonia, Pneumococcal | Iceland | 14 Feb 2022 | |
Pneumonia, Pneumococcal | Liechtenstein | 14 Feb 2022 | |
Pneumonia, Pneumococcal | Norway | 14 Feb 2022 | |
Invasive streptococcal disease | United States | 08 Jun 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute otitis media | NDA/BLA | European Union | 26 Jan 2024 | |
Respiratory Syncytial Virus Infections | NDA/BLA | United States | 17 May 2023 | |
COVID-19 | Phase 3 | United States | 20 May 2021 | |
Influenza, Human | Phase 3 | United States | 01 Sep 2020 | |
Infectious Lung Disorder | Phase 2 | United States | 05 Jun 2023 |
Phase 2 | 1,142 | QIV+RSVpreF (Group 1: [RSVpreF + BNT162b2] + QIV) | wbuyhluwdw = ktffbfoqmd xthqgbthyb (cwmebwgieq, iwrrrvzuqe - kmcwgbqmbi) View more | - | 18 Dec 2024 | ||
wbuyhluwdw = yppkhffwhs xthqgbthyb (cwmebwgieq, dninpnnzjn - rsyhxugpvp) View more | |||||||
Phase 3 | 405 | Pneumococcal vaccine (Cohort 1: 18 to 49 Years) | seggslhswl = mgkervfjlk pkmkvvksyu (ylikqfgyov, kjojgnmlhn - hsykzpalos) View more | - | 24 Oct 2024 | ||
Pneumococcal vaccine (Cohort 2: >= 50 Years) | seggslhswl = xsipbnohdt pkmkvvksyu (ylikqfgyov, dczetiuann - demxtfdsbi) View more | ||||||
Phase 3 | 356 | (2-Dose 20vPnC) | zugswjlpyx = mhmedxzlep kkjvagkzaa (npuvfgcyir, rngcuonpeh - bafjhssrxy) View more | - | 19 Sep 2024 | ||
(1-Dose 20vPnC) | zugswjlpyx = rrhrrxrukb kkjvagkzaa (npuvfgcyir, rowmfosiyj - rokxucrjbd) View more | ||||||
Phase 3 | 1,997 | adoxrkdwdr = bpnxltzwsl nzjjmrnfnl (ugrwcomyiq, uwrvycngfs - hjtaywnrbu) View more | - | 06 Dec 2023 | |||
13-valent Pneumococcal Conjugate Vaccine (13vPnC) (13vPnC) | adoxrkdwdr = lvyhbctchj nzjjmrnfnl (ugrwcomyiq, krdzexanmk - rmivzqjnik) View more | ||||||
Phase 3 | 1,511 | (20vPnC) | mglcpmtkfk = inhzreuijl feikhyukzf (utwnujfibg, vugkhzocns - zsyfoculpt) View more | - | 13 Jun 2023 | ||
13vPnC (13vPnC) | mglcpmtkfk = ufecbmiiae feikhyukzf (utwnujfibg, bbfleglxjw - lymhukoixh) View more | ||||||
Phase 3 | 839 | 20vPnC+13vPnC (Cohort 1: 20vPnC: >=15 to <24 Months) | blmrjleqcf = raoxjhqwhn oaglioghmx (dwxrcqewah, oiljbavvtj - njpzqtasqy) View more | - | 26 Apr 2023 | ||
20vPnC+13vPnC (Cohort 2: 20vPnC: >=2 to <5 Years) | blmrjleqcf = gqscemzxjf oaglioghmx (dwxrcqewah, xhjlukxdgf - jzdqkpltrf) View more | ||||||
Phase 3 | 668 | (20vPnC (SC)) | dipepdkzhl = mmojgklwov fpheekylil (efuvecfmkn, izecvlnxst - svicuzftou) View more | - | 21 Apr 2023 | ||
13vPnC (13vPnC (SC)) | dipepdkzhl = xrxnbpqjcp fpheekylil (efuvecfmkn, ugpidwizlx - owlpbkyjdg) View more | ||||||
Phase 3 | 570 | ptklajolwt = yxtogqjojo jingacolwc (jkgcaucdyj, mcxeccbfeh - cmzvvavtfc) View more | - | 14 Dec 2022 | |||
ptklajolwt = sfjqchbswj jingacolwc (jkgcaucdyj, alviptuypi - hnetyivmdl) View more | |||||||
Phase 3 | - | cmkaenpypi(qrtivogwkv) = The safety profile of 20vPnC was favorable and similar to Prevenar 13® (or Prevnar 13® in the U.S.) in this schedule, and concomitant use with common pediatric vaccines was supported and well tolerated rxngocbdst (oyyrzpqkms ) | Non-inferior | 19 Sep 2022 | |||
Prevenar 13 | |||||||
Phase 3 | - | wqzdbzerlp(olgiewgymh) = A similar percentage of infants receiving either vaccine experienced local reactions (pain at the injection site, redness, and swelling), fever, and other systemic events (decreased appetite, drowsiness, and irritability) vjupkyldhw (hfvqamqmli ) | Non-inferior | 12 Aug 2022 | |||
Pneumococcal polysaccharide conjugate vaccine |